These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 18768783)

  • 41. Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells.
    Wang Z; La Rosa C; Mekhoubad S; Lacey SF; Villacres MC; Markel S; Longmate J; Ellenhorn JD; Siliciano RF; Buck C; Britt WJ; Diamond DJ
    Blood; 2004 Aug; 104(3):847-56. PubMed ID: 15090456
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adjuvant Peptide Pulsed Dendritic Cell Vaccination in Addition to T Cell Adoptive Immunotherapy for Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
    Ma CKK; Clancy L; Simms R; Burgess J; Deo S; Blyth E; Micklethwaite KP; Gottlieb DJ
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):71-77. PubMed ID: 28864137
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reconstitution of CMV pp65 and IE-1-specific IFN-γ CD8(+) and CD4(+) T-cell responses affording protection from CMV DNAemia following allogeneic hematopoietic SCT.
    Tormo N; Solano C; Benet I; Nieto J; de la Cámara R; López J; Garcia-Noblejas A; Muñoz-Cobo B; Costa E; Clari MA; Hernández-Boluda JC; Remigia MJ; Navarro D
    Bone Marrow Transplant; 2011 Nov; 46(11):1437-43. PubMed ID: 21243030
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of induction therapy on established CMV specific T cell immunity in living donor kidney transplantation.
    Stranavova L; Hruba P; Girmanova E; Tycova I; Slavcev A; Fronek J; Slatinska J; Reinke P; Volk HD; Viklicky O
    Physiol Res; 2018 May; 67(2):251-260. PubMed ID: 29303612
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations.
    Gratama JW; Brooimans RA; van der Holt B; Sintnicolaas K; van Doornum G; Niesters HG; Löwenberg B; Cornelissen JJ
    Cytometry B Clin Cytom; 2008 Jul; 74(4):211-20. PubMed ID: 18454493
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Expansion of cytomegalovirus pp65 and IE-1 specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation.
    Bao L; Dunham K; Stamer M; Mulieri KM; Lucas KG
    Biol Blood Marrow Transplant; 2008 Oct; 14(10):1156-1162. PubMed ID: 18804046
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.
    Boeckh M; Bowden RA; Storer B; Chao NJ; Spielberger R; Tierney DK; Gallez-Hawkins G; Cunningham T; Blume KG; Levitt D; Zaia JA
    Biol Blood Marrow Transplant; 2001; 7(6):343-51. PubMed ID: 11464977
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity.
    Boeckh M; Leisenring W; Riddell SR; Bowden RA; Huang ML; Myerson D; Stevens-Ayers T; Flowers ME; Cunningham T; Corey L
    Blood; 2003 Jan; 101(2):407-14. PubMed ID: 12393659
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.
    Neuenhahn M; Albrecht J; Odendahl M; Schlott F; Dössinger G; Schiemann M; Lakshmipathi S; Martin K; Bunjes D; Harsdorf S; Weissinger EM; Menzel H; Verbeek M; Uharek L; Kröger N; Wagner E; Kobbe G; Schroeder T; Schmitt M; Held G; Herr W; Germeroth L; Bonig H; Tonn T; Einsele H; Busch DH; Grigoleit GU
    Leukemia; 2017 Oct; 31(10):2161-2171. PubMed ID: 28090089
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease.
    Hobeika A; Osada T; Serra D; Peplinski S; Hanson K; Tanaka Y; Niedzwiecki D; Chao N; Rizzieri D; Lyerly H; Clay T; Morse M
    Cytotherapy; 2008; 10(3):289-302. PubMed ID: 18418774
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cytomegalovirus pp65 limits dissemination but is dispensable for persistence.
    Malouli D; Hansen SG; Nakayasu ES; Marshall EE; Hughes CM; Ventura AB; Gilbride RM; Lewis MS; Xu G; Kreklywich C; Whizin N; Fischer M; Legasse AW; Viswanathan K; Siess D; Camp DG; Axthelm MK; Kahl C; DeFilippis VR; Smith RD; Streblow DN; Picker LJ; Früh K
    J Clin Invest; 2014 May; 124(5):1928-44. PubMed ID: 24691437
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cognate CD4 T-cell licensing of dendritic cells heralds anti-cytomegalovirus CD8 T-cell immunity after human allogeneic umbilical cord blood transplantation.
    Flinsenberg TW; Spel L; Jansen M; Koning D; de Haar C; Plantinga M; Scholman R; van Loenen MM; Nierkens S; Boon L; van Baarle D; Heemskerk MH; Boelens JJ; Boes M
    J Virol; 2015 Jan; 89(2):1058-69. PubMed ID: 25378489
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adenovirally transduced dendritic cells induce bispecific cytotoxic T lymphocyte responses against adenovirus and cytomegalovirus pp65 or against adenovirus and Epstein-Barr virus EBNA3C protein: a novel approach for immunotherapy.
    Hamel Y; Blake N; Gabrielsson S; Haigh T; Jooss K; Martinache C; Caillat-Zucman S; Rickinson AB; Hacein-Bey S; Fischer A; Cavazzana-Calvo M
    Hum Gene Ther; 2002 May; 13(7):855-66. PubMed ID: 11975851
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation.
    Peggs KS; Verfuerth S; Pizzey A; Chow SL; Thomson K; Mackinnon S
    Clin Infect Dis; 2009 Dec; 49(12):1851-60. PubMed ID: 19911966
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation.
    Hanley PJ; Shaffer DR; Cruz CR; Ku S; Tzou B; Liu H; Demmler-Harrison G; Heslop HE; Rooney CM; Gottschalk S; Bollard CM
    Cytotherapy; 2011 Sep; 13(8):976-86. PubMed ID: 21539497
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Induction of CMV-specific T-cell lines using Ag-presenting cells pulsed with CMV protein or peptide.
    Einsele H; Rauser G; Grigoleit U; Hebart H; Sinzger C; Riegler S; Jahn G
    Cytotherapy; 2002; 4(1):49-54. PubMed ID: 11953041
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Surveillance of cytomegalovirus for antiviral efficacy and risk factors in allogeneic hematopoietic stem cell transplantation].
    Jia JS; Liu DP; Huang XJ; Wu T; Liu DH; Zhang YC; Su H; Wang JB; Zhou JR; Liu Q; Ying MY; Sun RJ; Duan X; Lu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Aug; 14(4):749-54. PubMed ID: 16928314
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects.
    Berencsi K; Gyulai Z; Gönczöl E; Pincus S; Cox WI; Michelson S; Kari L; Meric C; Cadoz M; Zahradnik J; Starr S; Plotkin S
    J Infect Dis; 2001 Apr; 183(8):1171-9. PubMed ID: 11262198
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Robust expansion of viral antigen-specific CD4+ and CD8+ T cells for adoptive T cell therapy using gene-modified activated T cells as antigen presenting cells.
    Melenhorst JJ; Solomon SR; Shenoy A; Hensel NF; McCoy JP; Keyvanfar K; Barrett AJ
    J Immunother; 2006; 29(4):436-43; discussion 365-6. PubMed ID: 16799339
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation.
    Ganepola S; Gentilini C; Hilbers U; Lange T; Rieger K; Hofmann J; Maier M; Liebert UG; Niederwieser D; Engelmann E; Heilbronn R; Thiel E; Uharek L
    Bone Marrow Transplant; 2007 Mar; 39(5):293-9. PubMed ID: 17262060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.